Dermapharm Holding SE (DMPHF)
47.69
0.00 (0.00%)
USD |
OTCM |
Oct 06, 16:00
Dermapharm Gross Profit Margin (Quarterly) : 33.36% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 33.36% |
| March 31, 2026 | 35.50% |
| December 31, 2025 | 33.55% |
| September 30, 2025 | 36.44% |
| June 30, 2025 | 32.46% |
| March 31, 2025 | 34.33% |
| December 31, 2024 | 32.90% |
| September 30, 2024 | 35.42% |
| June 30, 2024 | 28.81% |
| March 31, 2024 | 36.89% |
| December 31, 2023 | 27.19% |
| September 30, 2023 | 31.54% |
| June 30, 2023 | 21.27% |
| March 31, 2023 | 41.16% |
| December 31, 2022 | 40.26% |
| September 30, 2022 | 40.26% |
| June 30, 2022 | 26.25% |
| March 31, 2022 | 38.75% |
| December 31, 2021 | 45.70% |
| Date | Value |
|---|---|
| September 30, 2021 | 43.35% |
| June 30, 2021 | 41.49% |
| March 31, 2021 | 38.30% |
| December 31, 2020 | 33.36% |
| September 30, 2020 | 32.77% |
| June 30, 2020 | 28.66% |
| March 31, 2020 | 34.06% |
| December 31, 2019 | 32.83% |
| September 30, 2019 | 29.53% |
| June 30, 2019 | 30.05% |
| March 31, 2019 | 31.83% |
| December 31, 2018 | 28.88% |
| September 30, 2018 | 31.22% |
| June 30, 2018 | 28.97% |
| March 31, 2018 | 35.29% |
| December 31, 2017 | 31.03% |
| September 30, 2017 | 28.65% |
| June 30, 2017 | 29.36% |
| March 31, 2017 | 31.54% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| AstraZeneca PLC | 76.09% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
| Avadel Pharmaceuticals Plc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 22.72% |
| Return on Assets | 6.65% |
| Return on Invested Capital | 8.59% |
| Profit Margin (Quarterly) | 8.12% |
| Operating Margin (Quarterly) | 24.92% |
| Return on Net Operating Assets | 7.78% |